Xylyx Bio is disrupting the organ transplant paradigm by bringing first-in-class human organ grafts to patients to expand the supply of transplantable organs for life-saving clinical transplantation and lower costs for treating end-stage disease.
Investors 1
Mentions in press and media 2
| Date | Title | Description |
| 02.09.2021 | Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute | BROOKLYN, N.Y., Sept. 2, 2021 /PRNewswire/ -- Xylyx Bio, Inc., a biotechnology company developing groundbreaking solutions for drug discovery and tissue modeling and repair, announced today that it has been awarded a Small Business Innovati... |
| 01.09.2021 | Xylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery | NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results de... |
Reviews 0
